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Increased platelet retention in familial recurrent thrombotic
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Increased platelet retention in familial recurrent thrombotic thrombo-
cytopenic purpura. We studied two brothers with recurrent thrombotic
thrombocytopenic purpura (TTP). Platelet retention, measured with a
modified Adeplat S glass-bead test, was found to be increased during acute
episodes of TTP and during remissions. Values of platelet retention
ranged between 57 to 95% (normal range 16 to 34%). The continually
elevated values enabled us to investigate which fraction of the patients'
blood was responsible for the increased platelet retention and to evaluate
the effect of different treatments on this parameter. We found that the
patients' plasma increased the retention of normal platelets and of
platelets taken from a patient with von Willebrand's disease type III. This
activity was located in the clyoprecipitate fraction of plasma. Unusually
large von Willebrand factor (vWF) multimers were demonstrated in both
children during remission and decreased during relapse. Both fresh frozen
plasma (FFP) and a commercial factor VIII/vWF concentrate reduced
platelet retention when tested during remission. Treatment of both
siblings with FFP or factor VIIl/vWF concentrate was beneficial during
recurrences. We conclude that the elevated platelet retention is due to a
factor in the cryoprecipitate of the childrens' plasma, and that both FFP
and factor VItI/vWF concentrate are effective in decreasing platelet
retention.
Thrombotic thrombocytopenic purpura (TTP) is characterized
by microangiopathic anemia, thrombocytopenia, fever, neurolog-
ical manifestations and nephropathy [1]. This syndrome occurs
rarely in childhood but cases of recurrent TIP and TTP-like
variants have been reported [2—81. Few cases of familial TIP have
been described [3, 7—12], and the etiology has not been defined.
One study found that plasma from TIP patients caused sponta-
neous aggregation of normal platelets [13]. Two groups have
identified platelet aggregating factors in the plasma of TIP
patients during recurrences [14, 15]. Furthermore, unusually large
von Willebrand factor (ULvWF) multimers have been demon-
strated in the plasma of patients with relapsing TIP during
remission [2, 16]. The ULvWF multimers have a greater ability to
aggregate platelets than the largest normal plasma vWF multim-
ers [17]. These ULvWF multimers tend to disappear from the
patients' plasma during recurrences. This may be due to binding
to platelets [18]. The reappearance of ULvWF multimers in
plasma after recovery has been associated with recurrences [19].
Plasma transfusion or exchange are the recommended thera-
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pies for acute episodes of TIP [20]. Patients with chronic relaps-
ing TIP usually respond to several transfusions of fresh frozen
plasma (FFP) without the need for plasma exchange [2, 21]. Some
of these patients have also benefited from treatment with plasma
transfusions on a regular basis [2, 6]. It is not clear why this
treatment is effective. It has been speculated that plasma supplies
a deficient factor such as immunoglobulin or prostacyclin [20], or
one that is capable of breaking down ULvWF multimers [17]. The
clyosupernatant fraction of plasma has also been found to be
effective [22, 231. The reason for this may be an ULvWF process-
ing activity in this fraction of plasma [17]. Treatment with factor
VIII concentrate has also been beneficial in patients with TIP and
TIP-like variants [5, 6, 24].
In this report, we describe increased platelet retention in two
siblings with TIP during relapse and remission. The aim of this
study was to investigate which fraction of the patients' blood
(platelets or plasma) increased platelet retention and to evaluate
the effect of treatment with FFP or factor VIII/vWF concentrate
on this parameter.
Subjects
Patient 1 is a Caucasian boy, currently eight years old, with
blood group B Rh+. His parents are healthy and unrelated. He
has two younger brothers, one six-years-old described below
(Patient 2) and the other four-years-old and well. His maternal
uncle has chronic renal failure due to IgA nephritis. His maternal
great-grandmother died of pregnancy related complications. Since
age five he has had five episodes of TIP. The episodes were
precipitated by viral or bacterial infections. Attacks of TIP were
characterized by pallor and jaundice caused by hemolytic anemia,
purpura due to thrombocytopenia, fever, fluctuating neurological
symptoms such as disorientation and comprehension difficulties
and pathological urinalyses. Hemolytic anemia did not develop
during the last two episodes (for laboratory tests see Table 1).
Blood pressure and serum creatinine were normal during relapses
and remission. Glomerular filtration rate (GFR) remains normal.
The patient has a tendency to develop thrombocytopenia during
febrile infections even without other signs or symptoms of TIP.
The patient's HLA haplotype is A3,28, B5 [51] 8, Cw5w7, DR3,6
DQ1,2.
Patient 2 is the younger brother of Patient 1, currently six-years-
old. He has blood group B Rh+. He was hospitalized on the
second day of life due to anemia, thrombocytopenia and jaundice.
He was treated with phototherapy and discharged on the fourth
day of life. Since the age of 18 months he has had four attacks of
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Table 1. Laboratory findings during T1P episodes in Patient 1
Episode number Normal
valuesLaboratory test 1 2 3 4 5
Hemoglobin (glliter)° 79 102 108 118 118 105—150
Platelet count 23 70 116 48 121 140—400
X 1O9/lite,'
Creatinine pmol/liter" 44 46 44 41 49 27—62
Direct antiglobulin test neg neg nt nt nt neg
Lactate dehydrogenase 16 9.8 9.9
p.kat/liter"
9.5 14 <12
Haptoglobin g/liter° <0.14<0.14 0.83 nt nt 0.45—2.75
Bilirubin:
total .unol/liter1' 36 25 29 30 14 <20
conjugated pmollliter" nt nt nt 3 nt 0—4
C3 %° 119 126 110 nt nt 70—142
C4 %° 67 92 49 nt nt 60—166
Clq %° 73 120 79 nt nt 76—136
Peripheral blood smear NF NF NF NF NF NF
Urinalysis:
protein g/liter" 0.3 0.3 0.15—0.3 0.3 0.15—0.3 <0.15
RBC 5—10 5—10 <5 50—1 00 5—15 5 per HPF
casts: granular 2—5 2—5 0—3 1—3 0—i <2 per HPF
red cell 1 1—2 0 0—3 0 0 per HPF
Abbreviations are: NP, no fragmented red blood cells observed; HPF,
high power field; neg, negative; nt, not tested.
C The lowest value registered during each episodebThe highest value registered during each episode
C Results from first available test before initiation of therapy
'FTP. In comparison to Patient I this boy has had more pro-
nounced symptoms upon relapse. Attacks were characterized by
severe microangiopathic hemolytic anemia, severe thrombocyto-
penia, macroscopic hematuria, pathological urinalysis and fever
(for laboratory results see Table 2). Vomiting is usually the first
sign of an impending relapse. During the first attack tremor was
noted. Fluctuations in the state of consciousness were noted
during the fourth episode. A slight increase of serum creatinine
was noted during the first and fourth episodes. These episodes
occurred during febrile viral or bacterial infections. Blood pres-
sure was normal during episodes and after recurrences. GFR was
reduced to 82 ml/minhl.73 m2 after the second episode but has
normalized since then. This patient also has a tendency to develop
thrombocytopenia during febrile infections. The patient's HLA
haplotype is: A3,28, B5 [51] 7, Cw5w7, DR6 DQ1.
Patient with von Willebrand disease (vWD) type III
Blood from a 27-year-old Caucasian man with vWD type III
was used for in vitro experiments. The patient was devoid of
endogenous vWF in plasma and platelets and had not been
treated with vWF for a period of 10 days prior to the experiment.
This patient has blood group 0 Rh+.
Healthy volunteers
Blood from a 38-year-old Caucasian man and a 33-year-old
Caucasian woman were used for in vitro studies. The volunteers
were healthy and not treated with medications. The male volun-
teer has blood group A Rh+ and is referred to as healthy
volunteer 1. The female volunteer has blood group B Rh+ and is
referred to as healthy volunteer 2.
The study was approved by the Ethics Committee of the
University of Lund.
Table 2. Laboratory findings during TTP episodes in Patient 2
Laboratory test
Episode number Normal
values1 2 3 4
Hemoglobin g/liter°
Platelet count >< 109/liter°
30
19
54
22
91
34
95
24
105—150
140—400
Creatinine p.mol/litert' 55 34 38 57 27—62
Direct antiglobulin test neg neg neg nt neg
Lactate dehydrogenase
pkat/liter'
nt 32 21 80 <12
Haptoglobin g!liter° nt <0.14 0.80 nt 0.45—2.75
Bilirubin:
total Mmol/liter" 51 67 38 75 <20
conjugated mol/liter" nt <1 nt nt 0—4
C3 %° 137 142 137 nt 70—142
C4 %° 123 132 99 nt 60—166
Clq %° nt 116 67 nt 76—136
Peripheral blood smear F & H F F & H nt NP
Urinalysis:
protein g/literh 1 1 0.15—0.30 3 <0.15
RBC 0 5—10 0—3 50 5 per HPF
casts: granular 2—5 10—15 2—5 5—10 2 per HPF
red cell 0 0 0-3 2—3 0 per HPF
Abbreviations are: F, fragmented red blood cells observed; H, Helmet
cells observed; NF, no fragmented red blood cells observed; HPF, high
power field.
C The lowest value registered during each episodebThe highest value registered during each episode; neg, negative; nt,
not tested
C Results from first available test before initiation of therapy
Methods
Study drug
Haemate® (Behring, Germany) a factor VIII concentrate con-
taining native vWF which was virus inactivated with wet heat
(60°C for 10 hr) [25] was injected intravenously during 10 minutes.
The vWF multimeric pattern of Haemate® is shown in Figure 3.
The ratio between vWF antigen and factor VIII (vWF:AgIVIII:C)
was 2.3, the ratio between ristocetin cofactor activity and factor
VIII (RCof/VIII:C) was 1.4.
FFP
The FFP units used in this study were obtained from healthy
adult donors. Plasma was obtained by apheresis and frozen at
—80°C within four hours. The vWF multimeric pattern of FFP
used in this study is shown in Figure 3. The concentration of vWF
antigen in the FFP was 0.81 lU/mi and ristocetin cofactor activity
was 1.14 IU/ml.
Bleeding time was measured with a Simplate-Il device (normal
range: 220 to 650 seconds) [26].
Blood collection
Venous blood for coagulation analysis was collected into 5 ml
silicone coated vacutainer tubes (Becton Dickinson) containing
0.5 ml 0.129 M sodium citrate. Platelet-poor plasma (PPP) was
obtained after centrifugation at 2000 >< g for 10 minutes. Most
samples were analyzed immediately. When this was not possible
the PPP was frozen immediately and stored at —70°C until
assayed.
Venous blood for platelet aggregation studies was collected into
10 ml polystyrene tubes containing 1 ml 0.129 M sodium citrate.
Platelet-rich plasma (PRP) was obtained by centrifugation at
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275 x g for 10 minutes and samples were analyzed immediately
afterwards.
Venous blood for analysis of tissue type plasminogen activator
(t-PA), urokinase type plasminogen activator (u-PA) and plasmin-
ogen activator inhibitor 1 antigen (PAl-I) was collected in Dia-
tube® H tubes (Stago Diagnostica, Asnières, France) containing
0.109 mmol of sodium citrate and inhibitors of platelet aggrega-
tion (theophylline, adenosine and dipyridamole). The samples
were immediately centrifuged at 2000 X g for 20 minutes at 4°C
and the PPP frozen until assayed.
von Willebrand factor antigen
von Willebrand factor antigen (vWF:Ag) was assayed with an
immunoradiometric assay (IRMA) using a monoclonal antibody
against vWF (normal range 0.5 to 2.0 IU/ml) [27, 28]. Pooled
citrated plasma from 20 healthy subjects was calibrated against
the 1st British standard (85/644) for analyses of vWF:Ag. Results
were expressed in lU/mI.
Ristocetin cofactor activity
Ristocetin cofactor activity (RCof) was determined as previ-
ously described by Zuzel, Nilsson and Aberg [29]. The normal
range is 0.68 to 1.40 IU/ml.
Platelet counts
Platelets were counted visually by phase microscopy or with an
automated hematology analyzer (Coulter STKS) (normal range
140 to 400 X 109/liter).
Platelet aggregation
Platelet aggregation was performed with an optical method in a
Lumi-aggregometer (Chrono-Log Haverton, PA, USA) as de-
scribed before [301.
Ristocetin-induced platelet aggregation (RIPA)
PRP was diluted with PPP to a platelet count of 250 X 109/liter.
Five hundred microliters PRP were added to cuvettes of a
Lumi-aggregometer. Aggregation was induced by adding 20 il
ristocetin, final concentrations varying from 0 to approximately
2.0 mg/mI. The lowest ristocetin concentration able to induce
aggregation was titrated and compared to the results obtained
with platelets from a normal person.
Multimeric structure of vWF
The multimeric structure of vWF (multimeric sizing) in PPP
was analyzed with sodium dodecyl sulfate agarose gel electro-
phoresis (1.9% agarose concentration) as described elsewhere
[311. The multimeric bands were identified with a blotting tech-
nique [32].
Preparation of plasma ciyoprecipitate and ctyosupernatant
Citrated PPP were frozen at —70°C, thawed at 4°C for three
hours and afterwards centrifuged at 4500 g at 4°C for 20 minutes.
The cryosupernatant was separated from the cryoprecipitate and
the latter was dissolved in a buffer (6% bovine serum albumin,
0.01 M phosphate and 0.15 M NaCl, pH 7.4). The cryosupernatant
and the dissolved cryoprecipitate were thereafter immediately
used for analysis of platelet retention as described below.
Platelet retention
Platelet retention was measured with a modified Adeplat S test
(Semmelweis, Milan, Italy) based on Hellem's method, as de-
scribed before [301. Briefly, citrated blood was incubated in test
tubes for one hour at room temperature, afterwhich the tubes
were rotated. Approximately 1 ml blood was transferred to a
plastic tube containing EDTA dipotassium salt and marked
"control." After priming the micro-bead filter with 1 ml of blood,
another 1 ml of blood was passed through the filter into a test tube
containing EDTA dipotassium salt, marked "test." A total of 0.1
ml blood was drawn from the test tubes marked "control" or
"test" and transferred to plastic tubes containing 1.9 ml% ammo-
nium oxalate solution to induce hemolysis of the erythrocytes.
Platelet suspensions were counted by phase microscopy in Burker
chambers. Platelet retention was calculated in % by the following
formula: ({cc — tc}/cc) X 100, where cc denotes control count and
tc test count. The normal range is 16 to 34%, based on results
obtained from 30 healthy volunteers (13 male and 17 female) aged
26 to 69 years (median 41.8 years).
Platelet retention before and after in vitro exchange of PPP
between blood samples from patients and healthy volunteer 1
To examine if plasma from the patients could affect retention of
platelets from a healthy volunteer, and vice versa, the following in
vitro exchange assays were carried out. Platelet retention was
tested in blood samples from each patient and from healthy
volunteer 1. Furthermore, blood samples from the patients and
from the healthy volunteer were centrifuged at 2000 >< g for 10
minutes, after which the PPP was removed. The PPP from each
patient was replaced by an equal volume of PPP from the healthy
volunteer. The volumes of PPP from Patient 1 and from the
healthy volunteer were equal. However, the amount of PPP
derived from the healthy volunteer was smaller (2.6 ml) than the
amount derived from Patient 2 (2.7 ml). Due to this, a small
fraction of PPP from Patient 2 (0.1 ml) was added to PPP from the
healthy volunteer (2.6 ml) before combining with the blood cells
from Patient 2. Each patient's blood cells were then gently mixed
with the healthy volunteer's PPP and further incubated at room
temperature for one hour. After this period, platelet retention was
analyzed. The reverse experiment was also carried out in which
PPP from the patient was added to the blood cells of the healthy
volunteer, mixed and incubated for one hour, after which platelet
retention was analyzed. The in vitro exchange of PPP between
patient 1 and the healthy volunteer is demonstrated in Figure 1 of
the results. To rule out the possibility that centrifugation per se
effected platelet retention, a blood sample from the individuals
(patients and healthy volunteer) was centrifuged at 2000 X g for
10 minutes, after which the blood cells and plasma were gently
remixed. After incubation at room temperature for a period of
one hour platelet retention was tested.
Platelet retention before and after in vitro exchange of PPP
between blood samples from healthy volunteers I and 2
The possibility that plasma exchange between individuals with
different blood groups may affect platelet retention was investi-
gated by performing the above-mentioned procedure, for in vitro
exchange of PPP, between blood samples from healthy volunteers
1 and 2.
Patient 1
en
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Healthy volunteer 1
blood cells plasma plasma blood cells blood cells plasma
Fig. 1. Platelet retention before and after in vitro plasma exchange between Patient 1 and healthy volunteer 1.
centrifuged
blood cells plasma
vWD plasma &
blood cells from
Patient 2
centrifuged
,-,\
blood cells plasma
Patient 2 & vWD plasma
(1:1)& blood cells from
Patient 2
Platelet
retention
35%
centrifugedZN
vWD & Patient 2 plasma
(1:1)& blood cells from
vWD patient
Fig. 2. Platelet retention before and after in vitro plasma exchange between Patient 2 and a patient with von Willebrand disease type III.
Platelet retention before and after in vitro exchange of plasma
between blood samples from Patient 2 and a patient with vWD
type III
To evaluate if plasma devoid of vWF affected retention of
platelets from a TFP patient and if patient plasma effected retention
of platelets devoid of vWF, the above-mentioned procedure for in
vitro exchange of PPP was also carried out between blood samples
from Patient 2 and a patient with severe vWD type III. In addition
to these experiments, PPP from Patient 2 and from the patient
with vWD was combined to form a 1:1 mixture. Volumes of this
plasma mixture, equivalent to the volume of PPP obtained from
each individual after centrifugation, were added to blood cells
from Patient 2 and the patient with vWD, respectively. The
plasma mixture and blood cells were mixed, incubated at room
temperature for one hour and platelet retention was analyzed as
described. These experiments are demonstrated in Figure 2.
Platelet retention before and after addition of cryoprecipitate and
ctyosupematant of patients'plasma to normal platelets
The following experiment was carried out in order to investi-
gate which fraction of the patients' plasma affected retention of
normal platelets. The platelet retention of healthy volunteer 1 was
centrifuged/\centrifuged/\
blood cells plasma\/
resuspended
centrifuged/\ centrifuged/\
resuspended
Platelet Platelet Platelet Platelet Platelet Platelet
retention retention retention retention retention retention
67% 72% 26% 52% 24% 22%
Patient 2
rio rio 00
vWD patient
00 00
centrifugedZN
plasma blood cells
Patient 2 plasma
& blood cells from
vWD
Platelet
retention
71%
Platelet
retention
17%
Platelet Platelet Platelet
retention retention retention
46% 80% 14%
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Table 3. Coagulation studies Patient 1 during remission
Treatment FFP 200 ml Haemate® 500 IU Haemate® 250 IU
After After After
1 hr 5 Days Before 1 hr
nt N N N
2.88 2.62 2.66 2.88
1.15 1.77 nt >2 nt nt
nt UL dUL UL UL UL nt UL UL
nt 0.9/1.0 0.8/1.0 nt 0.7/1.0 0.6/1.0
-
0.6/1.0 nt nt
Abbreviations are: nt, not tested; N, normal; MS, multimcr structure of vWF; UL, ultra large multimers of vWF present; dUL, decrease of ULvWF
multimers; RIPA, ristocetin induced platelet aggregation.
The lowest ristocetin concentration able to induce aggregation: patient/normal
Before Before Before5 Days Before
Platelet count 174 187 255 232 210 236 203 219 201 224
(140—400 X 109/liter)
Platelet retention 68 18 25 57 51 95 85 76 67 55
(16 —34%)
Platelet aggregation N N nt nt nt nt nt nt nt nt
vWF IRMA 1.75 1.86 1.89 nt nt 3.14 4.42 3.52 3.20 3.33
(0.56—2.00 JE/mI)
RCof 2.50 1.36 1.36 nt nt 3.0 4.0 1.24 2.75 3.50
(0.68—1.40 JE/mI)
MS UL UL N nt nt UL UL UL UL UL
RIPA 0.6/0.8 0.7/0.8 0.7/1.0 nt nt nt nt nt 0.6/1.0 0.8/1.0
Abbreviations are: N, normal; nt, not tested; MS, multimer structure of vWF; UL, ultra large multimers of vWF present; RIPA, ristocetin induced
platelet aggregation.
The lowest ristocetin concentration able to induce aggregation: patient/normal
tested. Furthermore, several blood samples from the same volun-
teer were centrifuged at 2000 X g for 10 minutes, the PPP was
removed and replaced by an equal amount of the plasma cryosu-
pernatant or cryoprecipitate from Patient 1. As a control, an equal
amount of the buffer used to dissolve the cryoprecipitate was
added to the healthy volunteer's blood cells separately. The
normal blood cells were then gently mixed with the patient's
plasma cryosupernatant, cryoprecipitate or buffer and incubated
at room temperature for one hour. After this period platelet
retention was tested as described above.
Tissue plasminogen activator
Tissue plasminogen activator (t-PA) was measured with an
enzyme-linked immunosorbent assay (ELISA) Imulyse t-PA kit
(Biopool, Umeâ, Sweden). The normal plasma concentration is 3
to 10 ng/mI [331.
Urinary plasminogen activator
Urinary plasminogen activator (u-PA) was measured with an
immunosorbent assay (Chromolize u-PA, Biopool), which de-
tects both single chain (scu-PA) and 54 kDa two chain (tcu-PA)
u-PA. The normal plasma concentration is 0.20 0.18 ng/ml [34,
35].
Plasminogen activator inhibitor-i
Plasminogen activator inhibitor-i (PAl-I) antigen was mea-
sured with an ELISA (Imulyse PAl-I, Biopool) [361. The
normal plasma concentration is 4 to 43 ng/mI.
PAl-i activity was measured with a chromogenic method
(Spectrolyse® fibrin, Biopool). The normal plasma concentration
is 0 to 15 U/ml [371.
Results
Tables I and 2 present laboratory data during TTP episodes for
Patients 1 and 2, respectively.
Increased platelet retention during remission and relapse
Platelet retention as measured in a platelet retention test was
markedly increased in both patients during remissions (Tables 3
and 4). Platelet retention was measured upon relapse of Patient 2
(prior to the administration of therapy for the fourth TIP
episode) revealing a value of 71%. Platelet retention measured in
Analysis
(normal value) 0 Before
After
1 hr
After
5 days
Platelet count
(140—400 >< 109/Iiter)
Platelet retention
(16—34%)
Platelet aggregation
vWF IRMA
(0.56 —2.00 IE/ml)
RCof
(0.68—1.40 IE/mI)
MS
RIPA
Before
254 261 277 233 176 202 182 288
90 76 39 75 95 63 80 67
nt N N
1.76 1.47 2.40
1.62 1.30 2.48
290
38
nt
2.23
nt
1.73
Treatment
Analysis
(normal value)
Table 4. Coagulation studies Patient 2 during remission
After
1 hr
FFP 200 ml Haemate® 500 IU
After
1 hr
After After
Ohr 4hr
Haemate® 250 IU
After
1 hr
a s
——
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Patient 1 five days after the onset of the fourth TTP episode (14 P
hr after treatment) showed a 72% retention. Platelet retention
was found to be normal in the healthy younger brother (20%),
mother and father (21% and 17%, respectively).
Plasma taken from patients during remission increased retention of
normal platelets in vitro
In an attempt to define if the increased platelet retention found
in these patients was due to a factor in their plasma or their
platelets, in vitro experiments were carried out as shown in Figure
1 for Patient 1, Addition of plasma from Patient I to normal
platelets increased platelet retention from 22% to 52%. Addition
of normal plasma to platelets from Patient 1 decreased platelet
retention from 67% to 26%. Similar results were obtained for
Patient 2. The patient's platelet retention was 73% and the
healthy volunteer's platelet retention was 19%, Addition of
plasma from Patient 2 to normal platelets increased platelet
retention from 19% to 59%. When normal plasma was added to
platelets from Patient 2 this was combined with a small amount of
the patient's own plasma as described above and platelet retention
decreased from 73% to 42% (platelet retention did not decrease
to within the normal range). These experiments were carried out
during remission.
To exclude the possibility that the changes in platelet retention
were due to activation of isoagglutitnins in blood groups A versus
B and vice versa, in vitro experiments were carried out between
healthy volunteers I and 2. Healthy volunteer 1 had 26% platelet
retention and healthy volunteer 2 had 16% platelet retention.
Addition of plasma from healthy volunteer 1 to platelets from
healthy volunteer 2 resulted in 21% platelet retention. Addition of
plasma from healthy volunteer 2 to platelets from healthy volun-
teer 1 resulted in 26% platelet retention.
Plasma ciyoprecipitate from Patient 1 increased retention of
normal platelets in vitro
The plasma fraction which increased platelet retention was
investigated in vitro by adding the cryosupernatant or cryoprecip-
itate fraction of plasma from Patient 1 to normal platelets.
Healthy volunteer 1 had 17% platelet retention. Addition of
plasma cryoprecipitate taken from Patient 1 during remission to
the volunteer's platelets increased platelet retention to 93%.
Addition of plasma cryoprecipitate taken from the onset of this
patient's fourth TTP episode to the volunteer's platelets increased
platelet retention to 95%. Addition of the patients' cryosuperna-
tant from remission to the normal platelets gave 13% platelet
retention and cryosupernatant from relapse gave 18% platelet
retention. Addition of the buffer used to dissolve the plasma
cryoprecipitate to the normal platelets resulted in 18% platelet
retention.
Plasma taken from Patient 2 upon relapse increased retention of
platelets from a patient with vWD type III in vitro
To study the role of vWF in the enhanced platelet retention, in
vitro experiments were carried out adding plasma from Patient 2
to platelets from a patient with vWD type III and vice versa.
Addition of plasma taken from Patient 2 upon relapse to platelets
from the patient with vWD resulted in an increase of platelet
retention from 14% to 80% (Fig. 2). Addition of plasma from the
patient with vWD to platelets from Patient 2 resulted in decrease
CS CP H
Fig. 3. The vWF multimeric pattern of normal fresh frozen plasma used in
this study (P), plasma cyosupernatant (CS), plasma ctyoprecipitate (P,}
and Haemate® (H. Haemate® has a multimeric pattern similar to normal
plasma but lacking the ULvWF multimers found in TFP plasma.
of platelet retention from 71% to 17%. Combining equal amounts
of plasma from Patient 2 and plasma from the patient with vWD
with platelets from Patient 2 decreased platelet retention to 35%.
Combining equal amounts of plasma from Patient 2 and plasma
from the patient with vWD with platelets from the latter resulted
in 46% platelet retention. Similar studies were not carried out for
Patient 1.
Effect of FFP on platelet retention during remission
The administration of 200 ml FFP during remission reduced
platelet retention in Patient 1 from a value of 76% prior to
treatment to 39% one hour after treatment (Table 3). Platelet
retention increased within five days to the pretreatment level, FFP
had a similar effect on platelet retention when tested in Patient 2
in which a reduction from 68% to 18% was noted one hour after
treatment and was still low five days later. This effect was,
however, not constant and when FFP was given at a later date only
a slight decrease in platelet retention from 57% prior to treatment
to 51% one hour after treatment was registered (Table 4).
The effect of Haemate® on platelet retention during remission
Intravenous administration of 500 IU Haemate® during remis-
sion reduced platelet retention in Patient 1 from 95% prior to
treatment to 63% one hour after treatment. Platelet retention
increased within five days to 80%. A lower dose of Haemate®, 250
IU, reduced platelet retention from 67% prior to treatment to
38% one hour later (Table 3). In Patient 2, Haemate® at a dose of
500 IU reduced platelet retention from 95% prior to treatment to
85% after one hour and 76% after four hours. Haemate® at a dose
of 250 IU reduced platelet retention from 67% prior to treatment
to 55% after one hour (Table 4).
The vWF multimeric pattern of Haemate® and FE?
The vWF multimeric pattern of normal FFP (analyzed from the
FFP given to Patient 1) was compared to the vWF multimeric
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Fig. 4. Hemoglobin and platelet counts in Patient I during TTP episodes in
relation to treatment. A and B TIP episodes 1 and 4, respectively. Symbols
are: (•) hemoglobin g/liter; (4) platelet Count- 10°/liter; (4) fresh frozen
plasma 10 to 15 mI/kg i.v.; () hydrocortisone 100 mg iv.; () Haemate®
500 IU iv.; and (0) Haemate® 250 IU iv.
pattern of Haemate®. Figure 3 shows that FFP and Haemate®
have similar vWF multimer structures. Haemate® has been pre-
viously shown to contain the larger plasma vWF multimers and
thus bears closer resemblance to plasma than most other factor
VIII/vWF concentrates [25]. Figure 3 also shows that Haemate
contains larger vWF multimers than plasma cryosupernatant.
Treatment with FFP and Haemate® during relapse and remission
Patient 1 has had five episodes of TTP from which he has
recovered within six days. During the first three episodes he was
treated intravenously with FFP 10 to 20 ml/kg/24 hr, and during
the fourth and fifth episodes he was treated with Haemate®.
Haemate was initially administrated at a dose of 500 IU (15
LU/kg) later reduced to 250 IU (7.5 lU/kg) at regular intervals.
Treatment was continued until sustained normalization of the
platelet count (> 140 X 10°/liter) was obtained. The clinical state
improved within one to two days and platelet counts normalized
within five days. Hemolysis was noted during the first three
episodes. During the fourth and fifth episodes hemolysis did not
develop. Figure 4a-b depicts the clinical course of the first and
fourth episodes, respectively.
After the second episode the patient received FFP infusions 10
mi/kg on a regular basis, this treatment was later replaced with
Haemate® 250 IU every third week until his fourth recurrence.
Since the fifth episode, which occurred five weeks after the fourth
episode, he has been treated with Haemate® 250 IU every other
week.
Patient 2 received one FFP infusion during the course of his
first episode of TIP. This episode was protracted and a sustained
normalization of the platelet count was first achieved after 36
days. Gradual clinical improvement occurred within two weeks.
The second attack was treated with plasma exchange and the third
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Fig. 5. Hemoglobin and platelet counts in Patient 2 during TTP episodes in
relation to treatment. A—C. TTP episodes 2 to 4, respectively. Symbols are:(•) hemoglobin g/liter; (4) platelet count 10°/liter; (*) blood transfu-
sion; (4) fresh frozen plasma 10 to 15 mI/kg iv.; (I—I) plasma exchange;
(LI) Haemate® 500 IU iv.; (0) Haemate® 250 IU iv.
attack was treated with infusions of FFP 10 to 15 ml/kg/24 hr.
Treatment was continued until sustained normalization of the
platelet count (> 140 x 10°/liter) was obtained. Figure 5a-b
depicts the clinical course of the second and third episodes,
respectively. During these recurrences clinical improvement was
observed within three to four days and platelet counts normalized
within five days. During the fourth episode the patient was initially
treated with Haemate® 500 IU (20 lU/kg) at six hour intervals
(Fig. Sc). Due to an increase in the serum creatinine level and
fluctuations in the state of consciousness during the first few
hours, FFP was administered after seven hours and during the
following three days, after which Haemate® treatment was re-
sumed. Doses of 500 IU (20 lU/kg) were later replaced by 250 IU
(10 lU/kg) and continued at regular intervals until sustained
normalization of the platelet count was obtained. Clinical im-
provement was noted after one day and the platelet count
normalized within six days. Hemolysis was documented during all
four TIP episodes. Since the last recurrence this boy has received
Haemate® 250 IU intravenously every second week.
VWF antigen and multimer structure during remission and relapse
High levels of vWF antigen and ULvWF multimers were
demonstrated in both patients during remissions (Tables 3 and 4).
The ULvWF multimers were located in the cryoprecipitate frac-
tion of plasma. Treatment with FFP and Haemate® increased the
S a
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Markers of endothelial cell activation
t-PA, u-PA, PAl-i antigen and PAl-i activity were analyzed as
markers of endothelial cell activation. t-PA, PAl-i antigen and
PAl-i activity taken from Patient 1 and 2 during remission were
found to be normal, u-PA was elevated during remission: 0.68
ng/ml in Patient 1 and 0.43 nglml in Patient 2. These tests were not
repeated during relapse.
Discussion
Fig. 6. Effect of 200 ml fresh frozen plasma i.v. on the multimeric sizing of
vWF in the plasma of Patient 1 during remission. ULvWF multimers were
found in plasma prior to treatment and decreased one hour after
treatment. vWF multimers in normal pooled PPP (NP), in PPP from
Patient I prior to treatment (Pre) and one hour after administration of
FFP (Post).
levels of vWF antigen during remission (Tables 3 and 4). FFP
given to Patient 1 during remission caused a decrease of the
ULvWF multimers (Fig. 6, Table 3). A decrease was also found in
Patient 2 five days after administration of FFP (Table 4).
Haemate® given to both patients during remission did not cause a
decrease in ULvWF multimers.
vWF antigen was measured at the onset of the fourth recur-
rence in Patient 1 and found to be increased to 3.14 lU/mi. A
further increase to 4.61 lU/mi was registered 12 hours later after
two treatments with Haemate® 500 IU.
The ULvWF multimers decreased after the onset of relapses. A
decrease in ULvWF multimers was also observed in the plasma of
Patient 1 twelve hours after the onset of the fourth TTP episode,
at which point two treatments with Haemate® 500 IU had been
administered. ULvWF multimers reappeared in the plasma of this
patient by the fifth day after the onset of this episode.
Side effects of FFP versus Haemate® treatment
FFP given during relapse resulted in fluid-colloid overload after
three to five days of treatment. Manifestations of fluid overload
were dyspnea and headache. A cardiac flow murmur was auscul-
tated in Patient 2 and chest X-ray of Patient 1 revealed small
amounts of fluid in the pleural sacs. Patient I repeatedly devel-
oped allergic urticaria during FFP treatments. To prevent this,
treatments were preceded by administration of clemastin per os
and hydrocortisone intravenously. No side effects were observed
during treatment with Haemate®.
In this study we found that platelet retention, as measured in a
glass-bead filter, was elevated in two siblings with recurrent TTP
during remission and relapse. Increased platelet retention has not
been previously documented in TTP or any other disease state.
However, platelet retention is enhanced by administration of
1-desamino-8-D-arginine vasopressin (DDAVP) to healthy volun-
teers [38].
The mechanism responsible for enhanced platelet retention is
not clear. Platelet retention may be the sum of platelet aggrega-
tion and adhesion within the glass-bead filter. The continually
elevated platelet retention in our patients enabled us to investi-
gate which fraction of blood was responsible for this elevation. We
found that it was due to a factor in the patients' plasma and not in
their platelets. The activity was localized to the cryoprecipitate
fraction of plasma. The ULvWF multimers, found in these
patients during remission, are also located in this fraction of
plasma. In vitro experiments in which plasma from the patients
was replaced by plasma with a normal vWF multimer structure
(from a healthy volunteer) or by plasma devoid of vWF (from a
patient with vWD type III) lowered platelet retention. These
experiments suggest that the ULvWF multimers may play a part in
the elevated platelet retention. These multimers decreased after
the onset of relapse. Platelet retention was, unfortunately, not
analyzed at various time points during relapses and we therefore
do not know if the decrease in ULvWF was followed by a decrease
in platelet retention. We have, however, shown that decreases in
ULvWF multimers induced by FFP treatment during remissions
were accompanied by a decrease in platelet retention.
Previous studies have shown that vWF is important for platelet
aggregation at high shear forces [39, 40] and that ULvWF
multimers are more effective than the vWF multimers normally
found in plasma [17]. Perfusion studies have demonstrated that
factor VIII/vWF induces platelet adhesion to subendothelium at
high shear rates [41, 42]. In a recent study, Moake et al have
shown that the platelets in citrated PRP from children with
relapsing TTP undergo excessive in vitro vWF-mediated shear-
induced aggregation [43]. In the platelet retention test used here
the blood is conceivably exposed to relatively high shear forces.
The test probably reflects vWF-dependent platelet aggregation as
well as adhesion, and the results indicate, by an independent
approach, the existence of a vWF-related plasma abnormality in
relapsing TTP.
DDAVP has been shown to increase endothelial output of
vWF, including ULvWF multimers [44] and is known to increase
platelet retention [38]. A previous study reported that adminis-
tration of DDAVP to a child with a similar syndrome induced a
relapse [5]. Thus, an increase in platelet retention may reflect
pathogenetic mechanisms in TTP.
The constantly enhanced platelet retention permitted us to
further investigate the role of vWF by therapeutic intervention. A
NP Post Pre
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comparison of the clinical course of Patient 2 during his first
episode, in which only one plasma treatment was given, with the
following relapses, in which daily treatment was given with FFP,
plasma exchange or Haemate®, indicates that these treatments
were beneficial and a speedier recovery was achieved, Treatments
may be efficacious by increasing the amount of "normal" vWF
multimers (those found in normal plasma), thereby reducing the
relative amount of ULvWF multimers. The vWF multimers bind
to platelet receptors GPIb and GPIIb-IIIa [45]. Due to their
multivalency, ULvWF multimers presumably bind to more GPIb
sites and thus have a greater capacity to promote platelet aggre-
gation and adhesion than smaller vWF multimers. The normal
vWF multimers administrated in Haemate® or FFP may compete
with the ULvWF multimers for platelet receptors. This would
thereby decrease platelet retention. Alternatively, the beneficial
effect of plasma may be due to a substance that processes the
ULvWF multimers to smaller multimers [17, 22, 23]. FFP may
have a combined effect decreasing platelet retention by the
binding of normal vWF multimers to platelet receptors, thereby
replacing the ULvWF multimers and processing the ULvWF into
smaller multimers by an as yet undefined substance.
Haemate® appeared to be as efficacious as FFP in lowering
platelet retention and treating TTP episodes. The effect of
Haemate® on platelet retention was not documented prior to and
after treatment during relapses due to the large amounts of blood
required for this test and because platelet retention is difficult to
assess in thrombocytopenic patients. Platelet retention measured
in patient I five days after the onset of relapse (14 hr after
administration of Haemate®) was elevated. Thus, even though
Haemate® was shown to decrease platelet retention when tested
during remission, this effect is, most probably, short-lived.
In comparison to FFP, treatment with Haemate® appears to
have certain advantages such as shorter preparation and admin-
istration periods. At the onset of symptoms a delay in adminis-
tration of therapy may cause further clinical deterioration. In-
deed, Patient 1 did not develop hemolysis during the two episodes
in which he was treated with Haemate®, most probably due to the
prompt administration of treatment. Other benefits of Haemate®
treatment are the lower risk of allergic reactions, colloid overload
and transmission of infectious disease.
Previous case reports have also found factor VIIl/vWF to be
beneficial in improving the clinical state of patients with TFP and
its variants [5, 6, 24]. A comparison between various plasma
components showed that a factor VIII concentrate induced an
increase in the platelet count whereas albumin, y globulin, factor
IX and fibronectin preparations did not [6].
The patients have continually elevated platelet retention even
during remission, and thus an extra stimulus must be necessary in
order to precipitate a relapse. Relapses occurred during infec-
tions. Infection induces a variety of host responses such as
cytokine elevation. We have previously shown that interleukin-6
and tumor necrosis factor alpha are increased in these patients
during relapse [46]. Endothelial cells are activated by cytokines
[47] and activated endothelial cells secrete ULvWF multimers [44,
48]. We speculate that a cytokine stimulus during infection may
further increase secretion of ULvWF from endothelial cells and
thus precipitate a recurrence of TFP in patients with elevated
platelet retention.
In summary, we have shown that two siblings with recurrent
TTP have elevated platelet retention during remission and relapse
due to a factor present in the cryoprecipitate fraction of plasma.
The ULvWF multimers, also found in this fraction of plasma,
seem to play a part in the enhanced platelet retention. Treatment
with FFP or factor V1II/vWF concentrate lowered platelet reten-
tion and promoted clinical improvement during recurrences.
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